My point is if those costs are included in the FY accounts being used to calculate break-even, then the revenue also needs to be included. If you are excluding BARDA revenue and costs from your analysis then that's fine, but the company doesn't in its full year statements.
- Forums
- ASX - By Stock
- Polynovo’s Novosorb is a med-tech Swiss Army Knife
My point is if those costs are included in the FY accounts being...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.06 |
Change
0.000(0.00%) |
Mkt cap ! $1.422B |
Open | High | Low | Value | Volume |
$2.07 | $2.08 | $2.04 | $1.857M | 901.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 11510 | $2.04 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.07 | 76972 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 11510 | 2.040 |
5 | 91305 | 2.030 |
2 | 4000 | 2.020 |
9 | 23969 | 2.010 |
11 | 23430 | 2.000 |
Price($) | Vol. | No. |
---|---|---|
2.070 | 36972 | 8 |
2.080 | 6972 | 2 |
2.090 | 10000 | 1 |
2.100 | 7200 | 1 |
2.110 | 4692 | 1 |
Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |